发明公开
EP2817331A1 USE OF THE CD2 SIGNALING DOMAIN IN SECOND-GENERATION CHIMERIC ANTIGEN RECEPTORS
审中-公开
VERWENDUNG DER CD2-SIGNALISIERUNGSDOMÄNEBEICHIMÄREN抗生素DER ZWEITEN GENERATION
- 专利标题： USE OF THE CD2 SIGNALING DOMAIN IN SECOND-GENERATION CHIMERIC ANTIGEN RECEPTORS
- 专利标题（中）： VERWENDUNG DER CD2-SIGNALISIERUNGSDOMÄNEBEICHIMÄREN抗生素DER ZWEITEN GENERATION
-
申请号： EP13751899.9申请日： 2013-02-22
-
公开(公告)号： EP2817331A1公开(公告)日： 2014-12-31
- 发明人: JUNE, Carl H. , SCHOLLER, John , POSEY, Avery, D.
- 申请人： The Trustees Of The University Of Pennsylvania
- 申请人地址： Center for Technology Transfer 3160 Chestnut Street, Suite 200 Philadelphia PA 19104-6282 US
- 专利权人： The Trustees Of The University Of Pennsylvania
- 当前专利权人： The Trustees Of The University Of Pennsylvania
- 当前专利权人地址： Center for Technology Transfer 3160 Chestnut Street, Suite 200 Philadelphia PA 19104-6282 US
- 代理机构： Grünecker, Kinkeldey, Stockmair & Schwanhäusser
- 优先权： US201261601907P 20120222
- 国际公布： WO2013126729 20130829
- 主分类号： C07K14/705
- IPC分类号： C07K14/705
摘要：
The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.
公开/授权文献
信息查询
